TherapeuticsMD (TXMD) Capital Expenditures Growth (3y) (2014 - 2023)
Powered by 
Analysis
TherapeuticsMD (TXMD) Capital Expenditures Growth (3y) (2014 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 5.53% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 21.85% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | -2.55% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -12.57% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -16.45% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 5.60% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | -40.95% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 139.61% |
| Sep 30, 2023 | -285.89% |
| Jun 30, 2023 | -361.98% |
| Mar 31, 2023 | -3.28% |
| Dec 31, 2022 | 176.41% |
| Jun 30, 2022 | -26.52% |
| Mar 31, 2022 | -45.71% |
| Sep 30, 2021 | -75.46% |
| Jun 30, 2021 | 29.65% |
| Mar 31, 2021 | 32.79% |
| Dec 31, 2020 | 86.33% |
| Jun 30, 2020 | -14.55% |
| Mar 31, 2020 | -8.96% |
| Dec 31, 2019 | 59.75% |
| Sep 30, 2019 | 185.86% |
| Jun 30, 2019 | 63.32% |
| Mar 31, 2019 | 52.17% |
| Dec 31, 2018 | 0.23% |
| Jun 30, 2017 | 3.31% |
| Mar 31, 2017 | 5.52% |